The targeted mechanism and scientific principles of Mavakatai (Mafantuo) in the treatment of cardiac hypertrophy

Mavacamten is a new oral myocardial infarction inhibitor specifically used to treat hypertrophic cardiomyopathy (HCM), especially obstructive hypertrophic cardiomyopathy (oHCM). HCMIt is a hereditary heart disease characterized by ventricular hypertrophy, cardiac chamber stenosis and diastolic dysfunction. It is often accompanied by symptoms of heart failure and risk of sudden death. The emergence of Mavaceta provides HCM patients with a treatment method that targets the pathological mechanism, which is different from traditional symptomatic treatment drugs such as β-blockers or calcium channel blockers.

The core mechanism of action of Mavaceta is selectively inhibiting the activity of the cardiac contractile protein—myosin (myosin). In HCM patients, overactivation of cardiac myosin leads to excessive myocardial contraction and increased energy consumption, which in turn leads to ventricular hypertrophy and impaired diastolic function. By reducing the interaction between myosin and actin, Mavacate reduces myocardial excessive contraction and restores myocardial diastolic function, thereby alleviating cardiac load and ventricular outflow tract obstruction.

At the molecular level, Mavacate can stabilize myosin in its "super-relaxed state" (super-relaxed state) and reduce unnecessary ATP consumption. This mechanism not only reduces myocardial contractility, but also reduces the metabolic pressure on myocardial cells and prevents further aggravation of myocardial fibrosis and ventricular hypertrophy caused by long-term excessive contraction. Through this targeted intervention, Mavaceta can directly regulate pathological myocardial contraction rather than simply improving symptoms through hemodynamics, so it is innovative and scientific in the treatment of HCM.

Mavacatel’s targeted mechanism makes it outstanding in improving ventricular outflow tract obstruction, improving exercise tolerance, and alleviating heart failure symptoms , and may also reduce the risk of sudden death. Clinical studies have shown that long-term use of Mavaceta can significantly improve ventricular diastolic function and patients' quality of life. In the future, with the understanding ofHCMWith in-depth research on pathological mechanisms, Mavakatai and similar new drugs targeting myosin are expected to become standardized and precise treatment options, providing patients with cardiac hypertrophy with a scientific treatment plan based on the pathological root cause.

Reference link:https://www.drugs.com